Doctors hail first breakthrough in asthma and COPD treatment in 5 decades

A recent trial has revealed a groundbreaking treatment for asthma and chronic obstructive pulmonary disease (COPD), marking the first significant advancement in 50 years, The Guardian reported yesterday.

The study, published in The Lancet Respiratory Medicine, found that the monoclonal antibody benralizumab, administered as an injection during flare-ups, is 30% more effective than traditional steroid tablets.

Lead investigator Prof. Mona Bafadhel from King’s College London noted that this approach targets eosinophils, white blood cells that contribute to lung inflammation. The trial involved 158 patients who experienced asthma or COPD attacks, with results showing improved respiratory symptoms and fewer treatment failures over 90 days for those receiving benralizumab.

The findings suggest that benralizumab could reduce the need for hospital visits and improve patients’ quality of life. Experts emphasize the urgent need for new treatments, as COPD is a leading cause of death worldwide.